Showing results (111-120 of 269) with videos related to
Sort By:
Pageof 27
Orphanet Journal of Rare Diseases|May 10, 2015
Biological parameters predictive of percent dense red blood cell decrease under hydroxyureaMarie Georgine Rakotoson, Gaetana Di Liberto, Etienne Audureau, et al.Haematologica|November 14, 2022
Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcersMansour Alkobtawi, Maria Sbeih, Karim Souaid, et al.American Journal of Blood Research|July 11, 2017
Erratum: Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopeniaBorhane Slama, Olivier Fain, Hervé Maisonneuve, et al.Transfusion|May 5, 2016
Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patientsClara Ibanez, Anoosha Habibi, Armand Mekontso-Dessap, et al.Medicine|May 8, 2015
Positron Emission Tomography With 18F-Fluorodeoxyglucose in Patients With Sickle Cell Acute Chest SyndromeNicolas de Prost, Myriam Sasanelli, Jean-François Deux, et al.International Journal of Hematology|July 24, 2015
Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostimDouglas B Cines, Terry Gernsheimer, Jeffrey Wasser, et al.British Journal of Haematology|October 10, 2024
When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?Sydney Dubois, Richard Layese, Nicolas Limal, et al.Blood Advances|October 7, 2024
Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopeniaAlexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, et al.Current Medical Research and Opinion|April 13, 2012
A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopeniaIlene Weitz, Miguel A Sanz, David Henry, et al.American Journal of Hematology|November 21, 2013
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodiesMehdi Khellaf, Amèlie Chabrol, Matthieu Mahevas, et al.Pageof 27